Pimavanserin | List of Frontiers open access articles

Original Research

Published on 06 Sep 2022

Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia

in Schizophrenia

Dragana Bugarski-Kirola
Rene Nunez
Ramzey Odetalla
I-Yuan Liu
Mary Ellen Turner

Frontiers in Psychiatry

doi 10.3389/fpsyt.2022.892199

3,932 views
6 citations

Brief Research Report

Published on 30 Aug 2023

Pimavanserin treatment increases plasma brain-derived neurotrophic factor levels in rats

in Neuropharmacology

Ashutosh Tripathi
Henry A. Nasrallah
Anilkumar Pillai

Frontiers in Neuroscience

doi 10.3389/fnins.2023.1237726

3,482 views
5 citations

Original Research

Published on 07 Dec 2018

Pimavanserin and Lorcaserin Attenuate Measures of Binge Eating in Male Sprague-Dawley Rats

in Neuropharmacology

Amanda E. Price
Victoria D. Brehm
Jonathan D. Hommel
Noelle C. Anastasio
Kathryn A. Cunningham

Frontiers in Pharmacology

doi 10.3389/fphar.2018.01424

4,298 views
13 citations

Original Research

Published on 05 Oct 2022

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis

in Dementia and Neurodegenerative Diseases

Victor Abler
Cecilia Brain
Clive Ballard
Ana Berrio
Bruce Coate
Alberto J. Espay

Frontiers in Neurology

doi 10.3389/fneur.2022.919778

4,811 views
13 citations

Mini Review

Published on 26 Feb 2020

Pimavanserin: A Novel Antipsychotic With Potentials to Address an Unmet Need of Older Adults With Dementia-Related Psychosis

in Neuropharmacology

Ismaeel Yunusa
Marie Line El Helou
Saud Alsahali

Frontiers in Pharmacology

doi 10.3389/fphar.2020.00087

20,378 views
32 citations

Study Protocol

Published on 30 Apr 2020

Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol

in Neuropharmacology

Olga B. Baltzersen
Herbert Y. Meltzer
Vibe G. Frokjaer
Jayachandra M. Raghava
Lone Baandrup
Birgitte Fagerlund
Henrik B.W. Larsson
H. Christian Fibiger
Birte Y. Glenthøj
Gitte M. Knudsen

Frontiers in Pharmacology

doi 10.3389/fphar.2020.00591

7,391 views
16 citations

Mini Review

Published on 06 Dec 2019

The Use of Antipsychotic Drugs for Treating Behavioral Symptoms in Alzheimer’s Disease

in Neuropharmacology

Valeria Calsolaro
Rachele Antognoli
Chukwuma Okoye
Fabio Monzani

Frontiers in Pharmacology

doi 10.3389/fphar.2019.01465

30,478 views
59 citations

Review

Published on 16 Feb 2023

The pharmacogenetics of the new-generation antipsychotics – A scoping review focused on patients with severe psychiatric disorders

in Psychopharmacology

Octavian Vasiliu

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1124796

11,563 views
17 citations

Articles

Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia

Pimavanserin treatment increases plasma brain-derived neurotrophic factor levels in rats

Pimavanserin and Lorcaserin Attenuate Measures of Binge Eating in Male Sprague-Dawley Rats

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis

Pimavanserin: A Novel Antipsychotic With Potentials to Address an Unmet Need of Older Adults With Dementia-Related Psychosis

Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol

The Use of Antipsychotic Drugs for Treating Behavioral Symptoms in Alzheimer’s Disease

The pharmacogenetics of the new-generation antipsychotics – A scoping review focused on patients with severe psychiatric disorders